These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 30044792)

  • 1. A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia.
    López L; Vélez I; Asela C; Cruz C; Alves F; Robledo S; Arana B
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006653. PubMed ID: 30044792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL).
    Rabi Das VN; Siddiqui NA; Pal B; Lal CS; Verma N; Kumar A; Verma RB; Kumar D; Das P; Pandey K
    PLoS One; 2017; 12(3):e0174497. PubMed ID: 28355259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
    Guery R; Henry B; Martin-Blondel G; Rouzaud C; Cordoliani F; Harms G; Gangneux JP; Foulet F; Bourrat E; Baccard M; Morizot G; Consigny PH; Berry A; Blum J; Lortholary O; Buffet P;
    PLoS Negl Trop Dis; 2017 Nov; 11(11):e0006094. PubMed ID: 29155816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
    López L; Robayo M; Vargas M; Vélez ID
    Trials; 2012 May; 13():58. PubMed ID: 22594858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region.
    Gadelha EPN; Ramasawmy R; da Costa Oliveira B; Morais Rocha N; de Oliveira Guerra JA; Allan Villa Rouco da Silva G; Gabrielle Ramos de Mesquita T; Chrusciak Talhari Cortez C; Chrusciak Talhari A
    PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006850. PubMed ID: 30379814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica.
    Solomon M; Pavlotsky F; Leshem E; Ephros M; Trau H; Schwartz E
    J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):973-7. PubMed ID: 21129042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Response with intralesional Amphotericin B in the treatment of old world cutaneous leishmaniasis: a preliminary report.
    Mushtaq S; Dogra D; Dogra N
    Dermatol Ther; 2016 Nov; 29(6):398-405. PubMed ID: 27477764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
    Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers.
    Solomon M; Pavlotzky F; Barzilai A; Schwartz E
    J Am Acad Dermatol; 2013 Feb; 68(2):284-9. PubMed ID: 22858005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of cryotherapy plus topical Juniperus excelsa M. Bieb cream versus cryotherapy plus placebo in the treatment of Old World cutaneous leishmaniasis: A triple-blind randomized controlled clinical trial.
    Parvizi MM; Handjani F; Moein M; Hatam G; Nimrouzi M; Hassanzadeh J; Hamidizadeh N; Khorrami HR; Zarshenas MM
    PLoS Negl Trop Dis; 2017 Oct; 11(10):e0005957. PubMed ID: 28981503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.
    Oliveira LF; Schubach AO; Martins MM; Passos SL; Oliveira RV; Marzochi MC; Andrade CA
    Acta Trop; 2011 May; 118(2):87-96. PubMed ID: 21420925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh.
    Sundar S; Pandey K; Mondal D; Madhukar M; Kamal Topno R; Kumar A; Kumar V; Kumar Verma D; Chakravarty J; Chaubey R; Kumari P; Rashid MU; Maruf S; Ghosh P; Raja S; Rode J; den Boer M; Das P; Alvar J; Rijal S; Alves F
    PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012242. PubMed ID: 38900786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod.
    Hervás JA; Martín-Santiago A; Hervás D; Rojo E; Mena A; Rocamora V; Dueñas J
    Pediatr Infect Dis J; 2012 Jan; 31(1):97-100. PubMed ID: 21829140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
    Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World.
    López L; Valencia B; Alvarez F; Ramos AP; Llanos-Cuentas A; Echevarria J; Vélez I; Boni M; Rode J; Quintero J; Jiménez A; Tabares Y; Méndez C; Arana B
    PLoS Negl Trop Dis; 2022 Mar; 16(3):e0010238. PubMed ID: 35255096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis.
    Motta JO; Sampaio RN
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):331-5. PubMed ID: 21492255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.
    Brown M; Noursadeghi M; Boyle J; Davidson RN
    Br J Dermatol; 2005 Jul; 153(1):203-5. PubMed ID: 16029352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial.
    Machado PRL; Ribeiro CS; França-Costa J; Dourado MEF; Trinconi CT; Yokoyama-Yasunaka JKU; Malta-Santos H; Borges VM; Carvalho EM; Uliana SRB
    Trop Med Int Health; 2018 Sep; 23(9):936-942. PubMed ID: 29924907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical tamoxifen in the therapy of cutaneous leishmaniasis.
    Trinconi CT; Reimão JQ; Bonano VI; Espada CR; Miguel DC; Yokoyama-Yasunaka JKU; Uliana SRB
    Parasitology; 2018 Apr; 145(4):490-496. PubMed ID: 28274283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.